Skip to main content

Cyfuse

HardwareMinato-ku, Tokyo, JapanFounded 2010· One of 1739 Hardware companies tracked by AMPulse

Develops and sells the Regenova bio 3D printer system, which fabricates three-dimensional tissues and organs using a scaffold-free, needle-array-based 'Kenzan Method' for regenerative medicine applications.

CEO / Founder
Shizuka Akieda
Team Size
11-50
Stage
Public
Total Funding
$24.5M
Latest Round
IPO
Key Investors
JAFCO Group

Technology & Products

Key Products

Regenova Bio 3D Printer; Human 3D Mini-Liver models for drug testing

Technological Advantage

The scaffold-free approach is a key differentiator, potentially leading to more biologically functional tissues. The technology is protected by patents (e.g., US11339361B2, WO2017131241A1) and has been developed in collaboration with industrial partners like Shibuya Kogyo for robotic control. Its transition into clinical trials (e.g., knee bone-cartilage repair) validates its path to regulated medical applications.

Differentiation

Value Proposition

Enables the creation of complex, scaffold-free 3D cellular structures (like nerve conduits, blood vessels, and bone-cartilage interfaces) with high cell viability, accelerating regenerative medicine R&D and clinical translation.

How They Differentiate

Cyfuse's scaffold-free Kenzan Method contrasts with most competitors' extrusion-based or light-based bioprinting that often requires hydrogel scaffolds. This aims to produce more natural tissue structures and better cell-cell interactions.

Market & Competition

Target Customers

Research institutions, pharmaceutical companies, and regenerative medicine developers

Industry Verticals

Regenerative Medicine; Pharmaceutical Research; Medical Research

Competitors

Organovo; Aspect Biosystems; Allevi (3D Systems)

Growth & Milestones

Growth Metrics

Listed on the Tokyo Stock Exchange Growth Market in 2022; developing a new bio 3D printer with NSK for commercial production of 3D cell products.

Major Milestones

Founded (2010); Series A ~$4.8M (2013); Listed on Tokyo Stock Exchange Growth Market (2022); Initiated physician-led clinical trial for knee bone-cartilage repair (2024); Partnership with PHC for production tech (2025)

Notable Customers

NSK Ltd.; PHC Holdings Corporation